Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?. Issue 4 (December 2022)

• Record Type: Journal Article
• Authors: Marinos, Alejandro; Heslop, Helen E.
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 35:Issue 4(2022)
• Publication Date: 2022-12
• Subjects: Chimeric antigen receptor -- Acute lymphoblastic leukemia -- Allogeneic stem cell transplant; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2022.101414
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: Autologous T cells genetically modified with a CD19 chimeric antigen receptor are an effective therapy for children and adults with relapsed or refractory acute lymphoblastic leukemia with initial response rates ranging from 70 to 85%. Unfortunately, about half of these responding patients will subsequently relapse raising the question of whether allogeneic hemopoietic stem cell transplant should be considered as a consolidative therapy. Currently efforts are focused on defining risk factors for relapse to try and develop algorithms predicting which patients may benefit from allogenic transplant.